Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 20/20 | 1.00 |
| ▸ | KDR | P35968 | 1/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.59 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12847032 | 0.91 | BRAF (0.83) | BRAF | |
| SCHEMBL12847044 | 0.91 | BRAF (0.83) | BRAFMAPK14 | |
| SCHEMBL13603521 | 0.86 | BRAF (0.80) | BRAFMAPK14 | |
| SCHEMBL4458180 | 0.85 | BRAF (1.00) | BRAF | |
| SCHEMBL1796098 | 0.84 | BRAF (0.73) | BRAF | |
| SCHEMBL4473240 | 0.83 | BRAF (1.00) | BRAFKDRMAPK14TNNI3K | |
| SCHEMBL13568234 | 0.82 | BRAF (0.70) | BRAF | |
| SCHEMBL12847441 | 0.79 | BRAF (0.70) | BRAFMAPK14 | |
| SCHEMBL1794741 | 0.79 | BRAF (0.84) | BRAF | |
| SCHEMBL4464984 | 0.79 | BRAF (0.67) | BRAFMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812433-B1 | IMIDAZO[4,5-B]PYRIDIN-2-ONE AND OXAZOLO[4,5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC COMPOUNDS | CANCER REC TECH LTD (GB) | 2015-07-22 | — | — | EP | disclosed |
| EP-1812433-B1 | IMIDAZO[4,5-B]PYRIDIN-2-ONE AND OXAZOLO[4,5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC COMPOUNDS | CANCER REC TECH LTD (GB) | 2015-07-22 | — | — | EP | disclosed |
| US-7625922-B2 | Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-12-01 | — | — | US | disclosed |
| US-7625922-B2 | Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-12-01 | — | — | US | disclosed |
| US-7625922-B2 | Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-12-01 | — | — | US | disclosed |
| US-20070287838-A1 | Imidazo[4,5-B]Pyridin-2-One and Oxazolo[4,5-B]Pyridin-2-One Compounds and Analogs Thereof as Therapeutic Compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-12-13 | — | — | US | disclosed |
| US-20070287838-A1 | Imidazo[4,5-B]Pyridin-2-One and Oxazolo[4,5-B]Pyridin-2-One Compounds and Analogs Thereof as Therapeutic Compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-12-13 | — | — | US | disclosed |
| US-20070287838-A1 | Imidazo[4,5-B]Pyridin-2-One and Oxazolo[4,5-B]Pyridin-2-One Compounds and Analogs Thereof as Therapeutic Compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-12-13 | — | — | US | disclosed |
| EP-1812433-A1 | IMIDAZO[4,5-B]PYRIDIN-2-ONE AND OXAZOLO[4,5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC COMPOUNDS | Cancer Research Technology Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006043090-A1 | IMIDAZO[4,5-B]PYRIDIN-2-ONE AND OXAZOLO[4,5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287838-A1 | Imidazo[4,5-B]Pyridin-2-One and Oxazolo[4,5-B]Pyridin-2-One Compounds and Analogs Thereof as Therapeutic Compounds | NR2E1, NR0B1, BRAF | BRAF 3/4885KDR 167/4885MAPK14 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.